HEART TRANSPLANTATION - ADULT (HTX) -> HTX - Immunosuppression, Therapeutics and Pharmacology Abstracts

1293 - Efficacy and Safety of LCP-Tacrolimus (Envarsus XR®) Conversion Therapy in Heart Transplantation

Presentation Number
1293
Speakers
Session Name
POSTER SESSION 3 - POSTER SESSION: Pharmacy and Pharmacology
Date
Fri, Apr 24, 2020
Time
06:00 PM - 07:15 PM
Authors

Previous ePresentation
1290 - Lung Transplantation after Allogeneic Stem Cell Transplantation: A Single-Centre Experience

Next ePresentations
1296 - Evaluation of Central Line Thrombosis in Children with Heart Failure on Continuous Infusion Milrinone
1297 - Voriconazole Associated Adverse Drug Events and Drug Monitoring in Lung Transplant (LTx) Recipients
1298 - Tailored Immunosuppression Using CYP3A5 Metaboliser Status in Heart and Lung Transplant Cases - An Indian Study
1300 - Cytomegalovirus Immune Globulin (CMV-Ig): An Old Drug with Fewer Tricks - Removal of Prophylactic CMV-Ig Administration in CMV Mismatched Lung Transplant Recipients
1304 - Correction of Iron Deficiency with Intravenous Iron Replacement Immediately after Left Ventricular Assist Device Implant
1305 - Incidence of Major Bleeding Associated with International Normalized Ratio Greater Than 4.0 in a Cohort of Mechanical Circulatory Support Device Patients
1307 - Tricuspid Surgery and Pulmonary Thromboendarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
1308 - The Effect of Exercise on Endothelin 1 Level in Patients with Pulmonary Hypertension
1310 - Treatment of Drug- and Toxin-Induced Pulmonary Arterial Hypertension (PAH): Real-World Experience with Macitentan
1313 - Prognostic Significance of Echocardiographic Parameters in Predicting Early Decline in Patients with Pulmonary Arterial Hypertension